Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
805K
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
6
-
Shares change
-
-26.7K
-
Total reported value, excl. options
-
$2.00
-
Value change
-
-$18.4K
-
Number of buys
-
1
-
Number of sells
-
-2
-
Price
-
$0.33
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q4 2023
5 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q4 2023.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6 shares
of 805K outstanding shares and own 0% of the company stock.
Largest 10 shareholders include CITADEL ADVISORS LLC (34K shares), Federation des caisses Desjardins du Quebec (19 shares), Global Retirement Partners, LLC (6 shares), UBS Group AG (0 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (0 shares), SABBY MANAGEMENT, LLC (512K shares), ARMISTICE CAPITAL, LLC (206K shares), RENAISSANCE TECHNOLOGIES LLC (38.9K shares), TWO SIGMA SECURITIES, LLC (12.9K shares), and Qube Research & Technologies Ltd (200 shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.